Theranostics 2020; 10(19):8757-8770. doi:10.7150/thno.47317 This issue Cite

Research Paper

MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma

Abigail R Molloy1*, Chloé Najac1*, Pavithra Viswanath1, Aliya Lakhani1, Elavarasan Subramani1, Georgios Batsios1, Marina Radoul1, Anne Marie Gillespie1, Russell O Pieper2,3, Sabrina M Ronen1,2✉

1. Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA
2. Brain Tumor Center, University of California San Francisco, San Francisco, CA, USA
3. Department of Neurological Surgery, Helen Diller Research Center, University of California San Francisco, San Francisco, CA, USA
*Contributed equally

Citation:
Molloy AR, Najac C, Viswanath P, Lakhani A, Subramani E, Batsios G, Radoul M, Gillespie AM, Pieper RO, Ronen SM. MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma. Theranostics 2020; 10(19):8757-8770. doi:10.7150/thno.47317. https://www.thno.org/v10p8757.htm
Other styles

File import instruction

Abstract

Graphic abstract

Mutations in isocitrate dehydrogenase 1 (IDH1mut) are reported in 70-90% of low-grade gliomas and secondary glioblastomas. IDH1mut catalyzes the reduction of α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG), an oncometabolite which drives tumorigenesis. Inhibition of IDH1mut is therefore an emerging therapeutic approach, and inhibitors such as AG-120 and AG-881 have shown promising results in phase 1 and 2 clinical studies. However, detection of response to these therapies prior to changes in tumor growth can be challenging. The goal of this study was to identify non-invasive clinically translatable metabolic imaging biomarkers of IDH1mut inhibition that can serve to assess response.

Methods: IDH1mut inhibition was confirmed using an enzyme assay and 1H- and 13C- magnetic resonance spectroscopy (MRS) were used to investigate the metabolic effects of AG-120 and AG-881 on two genetically engineered IDH1mut-expressing cell lines, NHAIDH1mut and U87IDH1mut.

Results: 1H-MRS indicated a significant decrease in steady-state 2-HG following treatment, as expected. This was accompanied by a significant 1H-MRS-detectable increase in glutamate. However, other metabolites previously linked to 2-HG were not altered. 13C-MRS also showed that the steady-state changes in glutamate were associated with a modulation in the flux of glutamine to both glutamate and 2-HG. Finally, hyperpolarized 13C-MRS was used to show that the flux of α-KG to both glutamate and 2-HG was modulated by treatment.

Conclusion: In this study, we identified potential 1H- and 13C-MRS-detectable biomarkers of response to IDH1mut inhibition in gliomas. Although further studies are needed to evaluate the utility of these biomarkers in vivo, we expect that in addition to a 1H-MRS-detectable drop in 2-HG, a 1H-MRS-detectable increase in glutamate, as well as a hyperpolarized 13C-MRS-detectable change in [1-13C] α-KG flux, could serve as metabolic imaging biomarkers of response to treatment.

Keywords: IDH1 mutation, low grade glioma, hyperpolarized 13C magnetic resonance spectroscopy, AG-881, AG-120


Citation styles

APA
Molloy, A.R., Najac, C., Viswanath, P., Lakhani, A., Subramani, E., Batsios, G., Radoul, M., Gillespie, A.M., Pieper, R.O., Ronen, S.M. (2020). MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma. Theranostics, 10(19), 8757-8770. https://doi.org/10.7150/thno.47317.

ACS
Molloy, A.R.; Najac, C.; Viswanath, P.; Lakhani, A.; Subramani, E.; Batsios, G.; Radoul, M.; Gillespie, A.M.; Pieper, R.O.; Ronen, S.M. MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma. Theranostics 2020, 10 (19), 8757-8770. DOI: 10.7150/thno.47317.

NLM
Molloy AR, Najac C, Viswanath P, Lakhani A, Subramani E, Batsios G, Radoul M, Gillespie AM, Pieper RO, Ronen SM. MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma. Theranostics 2020; 10(19):8757-8770. doi:10.7150/thno.47317. https://www.thno.org/v10p8757.htm

CSE
Molloy AR, Najac C, Viswanath P, Lakhani A, Subramani E, Batsios G, Radoul M, Gillespie AM, Pieper RO, Ronen SM. 2020. MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma. Theranostics. 10(19):8757-8770.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image